John D Davis

List of Publications by Year
in descending order

68 papers	4,992 citations	172457 29 h-index	102487 66 g-index
76 all docs	76 docs citations	76 times ranked	7395 citing authors

#	Article	IF	Citations
1	Pharmacokinetics and Concentrationâ€Response of Dupilumab in Patients With Seasonal Allergic Rhinitis. Journal of Clinical Pharmacology, 2022, 62, 689-695.	2.0	7
2	Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection. JAMA - Journal of the American Medical Association, 2022, 327, 432.	7.4	81
3	Pharmacokinetics of Subcutaneous Dupilumab Injection With an Autoinjector Device or Prefilled Syringe. Clinical Pharmacology in Drug Development, 2022, , .	1.6	3
4	Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Singleâ€Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate. Journal of Clinical Pharmacology, 2021, 61, 90-104.	2.0	14
5	REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. New England Journal of Medicine, 2021, 384, 238-251.	27.0	1,483
6	A phase 2, openâ€label study of singleâ€dose dupilumab in children aged 6Âmonths to <6Âyears with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 464-475.	2.4	52
7	Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis. Advances in Therapy, 2021, 38, 2365-2378.	2.9	7
8	Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies. Journal of Pharmacokinetics and Pharmacodynamics, 2021, 48, 479-494.	1.8	15
9	Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics. British Journal of Clinical Pharmacology, 2021, 87, 3398-3407.	2.4	1
10	Base and Covariate Population Pharmacokinetic Analyses of Dupilumab in Adolescents and Children â‰¥6 to <12 Years of Age Using Phase 3 Data. Clinical Pharmacology in Drug Development, 2021, 10, 1345-1357.	1.6	4
11	Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 941-952.	2.5	8
12	The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis. Clinical Pharmacology and Therapeutics, 2021, 110, 1318-1328.	4.7	6
13	A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumab. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1332-1342.	2.5	2
14	Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. New England Journal of Medicine, 2021, 385, 1184-1195.	27.0	371
15	Population pharmacokinetics and exposureâ€“response modeling for evinacumab in homozygous familial hypercholesterolemia. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1412-1421.	2.5	4
16	REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. New England Journal of Medicine, 2021, 385, e81.	27.0	487
17	REGEN-COVÂ® antibody cocktail bioanalytical strategy: comparison of LC-MRM-MS and immunoassay methods for drug quantification. Bioanalysis, 2021, 13, 1827-1836.	1.5	4
18	Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. Journal of the American Academy of Dermatology, 2020, 82, 377-388.	1.2	155

#	Article	IF	Citations
19	Dupilumab in adolescents with uncontrolled moderateâ€toâ€severe atopic dermatitis: results from a phase <scp>II</scp> a openâ€label trial and subsequent phase <scp>III</scp> openâ€label extension. British Journal of Dermatology, 2020, 182, 85-96.	1.5	111
20	Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis. JAMA Dermatology, 2020, 156, 44.	4.1	297
21	Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis. JAMA Dermatology, 2020, 156, 131.	4.1	110
22	Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 405-414.	2.5	7
23	14148 Pharmacokinetics, safety, and efficacy of dupilumab in children aged â‰¥2 to <6 years with severe uncontrolled atopic dermatitis (LIBERTY AD PRE-SCHOOL). Journal of the American Academy of Dermatology, 2020, 83, AB19.	1.2	2
24	Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11Âyears old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. Journal of the American Academy of Dermatology, 2020, 83, 1282-1293.	1.2	214
25	Pharmacokinetics and Pharmacodynamics of Garetosmab (Antiâ€Activin A): Results From a Firstâ€inâ€Human Phase 1 Study. Journal of Clinical Pharmacology, 2020, 60, 1424-1431.	2.0	27
26	Base and Covariate Population Pharmacokinetic Analyses of Dupilumab Using Phase 3 Data. Clinical Pharmacology in Drug Development, 2020, 9, 756-767.	1.6	10
27	Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects. Clinical Pharmacology in Drug Development, 2020, 9, 742-755.	1.6	36
28	Conjunctivitis in dupilumab clinical trials. British Journal of Dermatology, 2019, 181, 459-473.	1.5	288
29	Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials. Journal of Drugs in Dermatology, 2019, 18, 804-813.	0.8	15
30	Evaluation of Potential Diseaseâ€Mediated Drugâ€“Drug Interaction in Patients With Moderateâ€toâ€Severe Atopic Dermatitis Receiving Dupilumab. Clinical Pharmacology and Therapeutics, 2018, 104, 1146-1154.	4.7	39
31	Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from) Tj ETQq1 1 0.784314 rgBT /Ov	4.4	
32	Combining â€œBottomâ€upâ€•and â€œTopâ€downâ€•Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDCâ€0941) Pharmacokinetics. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 747-755.	2.5	7
33	Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development. Biopharmaceutics and Drug Disposition, 2016, 37, 51-65.	1.9	57
34	Exploratory Population PK Analysis of Dupilumab, a Fully Human Monoclonal Antibody Against ILâ€4RÎ±, in Atopic Dermatitis Patients and Normal Volunteers. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 617-624.	2.5	57
35	Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach. Journal of Lipid Research, 2016, 57, 46-55.	4.2	18
36	Phase 1 Study Evaluating Safety, Tolerability, Pharmacokinetics and Immunogenicity of REGN2222 in Healthy Adults: A New Human Monoclonal RSV-F Antibody for RSV Prevention. Open Forum Infectious Diseases, 2015, 2, .	0.9	14

#	Article	IF	Citations
37	Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 495-497.	2.5	15
38	Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9. AAPS Journal, 2015, 17, 881-890.	4.4	17
39	A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-9.	2.5	40
40	Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors. Journal of Clinical Pharmacology, 2013, 53, 1103-1111.	2.0	31
41	Effect of Rifampin and Rifabutin on the Pharmacokinetics of Lersivirine and Effect of Lersivirine on the Pharmacokinetics of Rifabutin and 25-O-Desacetyl-Rifabutin in Healthy Subjects. Antimicrobial Agents and Chemotherapy, 2012, 56, 4303-4309.	3.2	15
42	Pharmacokinetic Effects of Coadministration of Lersivirine with Raltegravir or Maraviroc in Healthy Subjects. Antimicrobial Agents and Chemotherapy, 2012, 56, 887-892.	3.2	6
43	The Pharmacokinetics of Lersivirine (UK-453,061) and HIV-1 Protease Inhibitor Coadministration in Healthy Subjects. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 24-32.	2.1	3
44	The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects. European Journal of Clinical Pharmacology, 2012, 68, 1567-1572.	1.9	10
45	Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK-453,061), in healthy adult subjects. British Journal of Clinical Pharmacology, 2012, 73, 768-775.	2.4	14
46	The Use of Beat-to-Beat Electrocardiogram Analysis to Distinguish QT/QTc Interval Changes Caused by Moxifloxacin From Those Caused by Vardenafil. Clinical Pharmacology and Therapeutics, 2011, 90, 449-454.	4.7	11
47	A population approach to in vitroâ€“in vivo correlation modelling for compounds with nonlinear kinetics. Journal of Pharmacokinetics and Pharmacodynamics, 2011, 38, 317-332.	1.8	10
48	Pharmacokinetic Interactions of Maraviroc with Darunavir-Ritonavir, Etravirine, and Etravirine-Darunavir-Ritonavir in Healthy Volunteers: Results of Two Drug Interaction Trials. Antimicrobial Agents and Chemotherapy, 2011, 55, 2290-2296.	3.2	32
49	Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers. Clinical Therapeutics, 2010, 32, 1889-1895.	2.5	7
50	Translational pharmacokineticâ€“pharmacodynamic modelling; application to cardiovascular safety data for PFâ€00821385, a novel HIV agent. British Journal of Clinical Pharmacology, 2010, 69, 336-345.	2.4	17
51	Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment. Antiviral Therapy, 2009, 14, 831-837.	1.0	44
52	Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients. Aids, 2009, 23, 2115-2122.	2.2	39
53	Species differences in the multiple-dose pharmacokinetics of the non-nucleoside reverse transcriptase inhibitor (NNRTI) UK-453,061 in animals and man: implications for safety considerations. Xenobiotica, 2009, 39, 534-543.	1.1	14
54	Scintigraphic Study to Investigate the Effect of Food on a HPMC Modified Release Formulation of UK-294,315. Journal of Pharmaceutical Sciences, 2009, 98, 1568-1576.	3.3	33

#	Article	IF	Citations
55	The Effects of Averaging on Accuracy of IVIVC Model Predictions. Journal of Pharmaceutical Sciences, 2009, 98, 3829-3838.	3.3	7
56	A Holistic Strategy for Characterizing the Safety of Metabolites through Drug Discovery and Development. Chemical Research in Toxicology, 2009, 22, 1653-1662.	3.3	63
57	A Comparison of the Prediction Accuracy of Two IVIVC Modelling Techniques. Journal of Pharmaceutical Sciences, 2008, 97, 3422-3432.	3.3	35
58	Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man. Xenobiotica, 2008, 38, 620-640.	1.1	64
59	Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects. British Journal of Clinical Pharmacology, 2008, 65, 68-75.	2.4	32
60	Investigation of Regional Mechanisms Responsible for Poor Oral Absorption in Humans of a Modified Release Preparation of the Î±-Adrenoreceptor Antagonist, 4-Amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 537 Td (tetrahydroisoquinolin-yl)-5-(2-p Predict in Vivo Absorption. Drug Metabolism and Disposition, 2008, 36, 87-94.	3.3	12
61	Grapefruit Juice-Drug Interaction Studies as a Method to Assess the Extent of Intestinal Availability: Utility and Limitations. Current Drug Metabolism, 2008, 9, 785-795.	1.2	61
62	NONLINEAR ORAL PHARMACOKINETICS OF THE Î±-ANTAGONIST 4-AMINO-5-(4-FLUOROPHENYL)-6,7-DIMETHOXY-2-[4-(MORPHOLINOCARBONYL)-PERHYDRO-1,4-DIAZEPIN-1-YL]QUINOLINE IN HUMANS: USE OF PRECLINICAL DATA TO RATIONALIZE CLINICAL OBSERVATIONS. Drug Metabolism and Disposition, 2004, 32, 197-204.	3.3	29
63	Interpretation and Optimization of the Dissolution Specifications for a Modified Release Product with an In Vivoâ€“In Vitro Correlation (IVIVC). Journal of Pharmaceutical Sciences, 2004, 93, 571-581.	3.3	20
64	In vivo-in vitro correlation (IVIVC) modeling incorporating a convolution step. Journal of Pharmacokinetics and Pharmacodynamics, 2001, 28, 277-298.	1.8	51
65	Effect of norfloxacin on theophylline disposition: a comparison with other fluoroquinolones. Pharmaceutical Research, 1995, 12, 257-262.	3.5	9
66	Metabolism of theophylline and its inhibition by fluoroquinolones in rat hepatic microsomes. Xenobiotica, 1995, 25, 563-573.	1.1	4
67	Relationship between enoxacin and ciprofloxacin plasma concentrations and theophylline disposition. Pharmaceutical Research, 1994, 11, 1424-1428.	3.5	13
68	Simultaneous assay of fluoroquinolones and theophylline in plasma by high-performance liquid chromatography. Biomedical Applications, 1993, 621, 105-109.	1.7	37